Answers are grounded in this paper and cite their sources.
The paper presents desvenlafaxine, a member of the group of dual reuptake inhibitors norepinephrine (NE) and serotonin (5HT). The presented drug is a member of a group which also includes venlafaxine, duloxetine, milnacipran. The pharmacokinetics and pharmacodynamics, indications and specifics of desvenlafaxine use in the domain of sexual dysfunction, perimenopause, menopause and pain syndromes are presented. Particular emphasis was placed on comorbidity and interactions, followed by safety and tolerability, as well as overdose. Proven antidepressant desvenlafaxine action with dual basis of action on serotonin and norepinephrine, potentially good anxiolytic action, excellent safety when administered in adulthood, and a wide range of comedication and comorbidity, as well as simple dosing make this antidepressant a good choice especially in treatment of moderate to moderately sever forms of depression.
No takes yet. Share an insight, caveat, or question.
Milovanović et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: